UNSPSC 51381906: Valdecoxib

This classification denotes a cyclooxygenase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2919279Q3W. European Medicines Agency schedules Valdecoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05065MIG. Valdecoxib generally arises in the molecular formula C16H14N2O3S. The term VALDECOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 no. 3, 1999, list 42.) Most nations schedule valdecoxib under HS 29350090 and SITC 51580.

As of Q4 2014, VALDECOXIB remains the US FDA Preferred Term for this commodity. Valdecoxib bears US NLM identifiers UMLS ID C0913246 and NCI Concept Code C1869. SMILES: S(=O)(=O)(N)C1CCC(C2C(NOC2C)C2CCCCC2)CC1.

UNSPSC 51381906 Valdecoxib, a Commodity code, nominally names a specific nonsteroidal anti-inflammatory drug, but recent state and local procurement activity under this code centers on broader pharmaceutical and health-supply procurement rather than valdecoxib specifically. State and local governments are soliciting generic multi-source pharmaceuticals, over-the-counter products, naloxone, drug deactivation systems, and direct-to-manufacturer prescription programs through this classification. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix reflects both standalone county procurement and large cooperative purchasing vehicles that aggregate demand across multiple participating jurisdictions and states.

Recent activity spans Florida, Texas, and Minnesota. The Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026 with a response deadline of March 26, 2026, is the largest cooperative solicitation, requiring vendors to supply through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification; awards take effect July 1, 2026. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The Texas Health and Human Services Commission released an exploratory RFI on April 3, 2026 (HHS0017013) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling future formal procurement. The code shows fragmented but active demand across state health departments, county health systems, and cooperative purchasing platforms pursuing pharmaceutical supply and specialty health products.